牛牛AI助理已提取核心訊息
On February 20, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, announced its ongoing collaboration with Clearmind Medicine Inc., a biotech company developing psychedelic-derived therapeutics. Together, they are strengthening their international patent portfolio with the filing of three new patent applications under the Patent Cooperation Treaty. These applications focus on novel combinations of psychedelic compounds, including LSD, psilocybin, DMT, and SciSparc's proprietary ingredient CannAmide™. The patents, initially filed as provisional applications with the USPTO, aim to leverage the therapeutic advantages of these compounds. SciSparc's CEO, Oz Adler, expressed confidence in the value CannAmide™ adds to psychedelic therapeutics. The company is also advancing drug development programs for various conditions, including Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus, and owns a subsidiary selling hemp seed oil-based products on Amazon.
On February 20, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, announced its ongoing collaboration with Clearmind Medicine Inc., a biotech company developing psychedelic-derived therapeutics. Together, they are strengthening their international patent portfolio with the filing of three new patent applications under the Patent Cooperation Treaty. These applications focus on novel combinations of psychedelic compounds, including LSD, psilocybin, DMT, and SciSparc's proprietary ingredient CannAmide™. The patents, initially filed as provisional applications with the USPTO, aim to leverage the therapeutic advantages of these compounds. SciSparc's CEO, Oz Adler, expressed confidence in the value CannAmide™ adds to psychedelic therapeutics. The company is also advancing drug development programs for various conditions, including Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus, and owns a subsidiary selling hemp seed oil-based products on Amazon.
2024年2月20日，專門研究中樞神經系統疾病和罕見疾病的臨床階段製藥公司ScisPARC Ltd. 宣佈與開發迷幻藥衍生療法的生物技術公司Clearmind Medicine Inc. 持續合作。他們共同根據《專利合作條約》提交了三項新的專利申請，從而加強了其國際專利組合。這些應用側重於迷幻化合物的新組合，包括迷幻藥、迷幻藥、DMT和ScisPARC的專有成分CannaMide™。這些專利最初是作爲臨時申請向美國專利商標局提交的，旨在利用這些化合物的治療優勢。ScisPARC的首席執行官奧茲·阿德勒表示對CannaMide™ 爲迷幻療法增加的價值充滿信心。該公司還在推進針對各種疾病的藥物開發計劃，包括圖雷特綜合症、阿爾茨海默氏病、疼痛、自閉症障礙和癲癇持續狀態，並擁有一家在亞馬遜上銷售大麻籽油類產品的子公司。
2024年2月20日，專門研究中樞神經系統疾病和罕見疾病的臨床階段製藥公司ScisPARC Ltd. 宣佈與開發迷幻藥衍生療法的生物技術公司Clearmind Medicine Inc. 持續合作。他們共同根據《專利合作條約》提交了三項新的專利申請，從而加強了其國際專利組合。這些應用側重於迷幻化合物的新組合，包括迷幻藥、迷幻藥、DMT和ScisPARC的專有成分CannaMide™。這些專利最初是作爲臨時申請向美國專利商標局提交的，旨在利用這些化合物的治療優勢。ScisPARC的首席執行官奧茲·阿德勒表示對CannaMide™ 爲迷幻療法增加的價值充滿信心。該公司還在推進針對各種疾病的藥物開發計劃，包括圖雷特綜合症、阿爾茨海默氏病、疼痛、自閉症障礙和癲癇持續狀態，並擁有一家在亞馬遜上銷售大麻籽油類產品的子公司。
有用
沒用